Organization
Hunan Provincial People's Hospital, Changsha, China
5 abstracts
Abstract
Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.Org: Fujian Medical University Union Hospital, Fuzhou, China, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Ruijin Hospital North, Shanghai Jiao Tong University School of Medcine, Shanghai, China, Dongguan Kang Hua Hospitcal, Dongguan, China, The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China,
Abstract
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Linyi Cancer Hospital, Linyi, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China,
Abstract
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.Org: Stephenson Cancer Center at the University of Oklahoma, Macquarie University Cancer Institute, Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Hunan Provincial People's Hospital, Changsha, China, Linyi Cancer Hospital,
Abstract
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Hunan Cancer Hospital, Changsha, China, Yunnan Cancer Hospital, Kunming, China, The First Affiliated Hospital of Anhui Medical University, Hefei, China,
Abstract
Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The central hospital of lishui city, Lishui, China, Department of Gastroenterology,Harbin Medical University Cancer Hospital, Harbin, China, Hunan Provincial People's Hospital, Changsha, China,